Matches in Wikidata for { <http://www.wikidata.org/entity/Q66061370> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q66061370 description "assaig clínic" @default.
- Q66061370 description "clinical trial" @default.
- Q66061370 description "clinical trial" @default.
- Q66061370 description "clinical trial" @default.
- Q66061370 description "clinical trial" @default.
- Q66061370 description "ensaio clínico" @default.
- Q66061370 description "ensayo clínico" @default.
- Q66061370 description "ensayu clínicu" @default.
- Q66061370 description "essai clinique" @default.
- Q66061370 description "klinisch onderzoek" @default.
- Q66061370 description "клінічне випробування" @default.
- Q66061370 name "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers" @default.
- Q66061370 name "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers" @default.
- Q66061370 type Item @default.
- Q66061370 label "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers" @default.
- Q66061370 label "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers" @default.
- Q66061370 prefLabel "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers" @default.
- Q66061370 prefLabel "BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers" @default.
- Q66061370 P1050 Q66061370-181CC3ED-3958-42F4-B91C-4C8F0868A7C7 @default.
- Q66061370 P1132 Q66061370-DF817BB1-FDED-40C5-A59B-C4C17D58C0EF @default.
- Q66061370 P1476 Q66061370-62B89EEA-40BD-449A-AD70-9BBF61101CEB @default.
- Q66061370 P17 Q66061370-11770A1B-AE8E-40E5-BCCC-202E63E8AEC0 @default.
- Q66061370 P2899 Q66061370-86FCD6AB-C5EB-4CAA-A44D-03B0473D2409 @default.
- Q66061370 P3098 Q66061370-AC36E2CA-8B01-4536-9743-CDC71AFCACF7 @default.
- Q66061370 P31 Q66061370-2253B4CC-C476-4677-A283-7B9A506699B1 @default.
- Q66061370 P4844 Q66061370-A5D6B0D0-7440-4371-A4E8-F835E79A5C33 @default.
- Q66061370 P580 Q66061370-F0E3E33D-5C16-48C2-B0D4-124F6614C16F @default.
- Q66061370 P582 Q66061370-BEA2E142-0512-403E-B685-284783A61936 @default.
- Q66061370 P6099 Q66061370-9531995B-DE8F-483C-9A0E-78E51FD871CE @default.
- Q66061370 P6099 Q66061370-E69CC035-DAF1-49DE-B76B-40E5AB928D77 @default.
- Q66061370 P8363 Q66061370-703C3DAC-4E05-4E41-931E-86250C47FC7D @default.
- Q66061370 P1050 Q33525 @default.
- Q66061370 P1132 "+60" @default.
- Q66061370 P1476 "Phase I/II Trial of Ipilimumab or Nivolumab With BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies" @default.
- Q66061370 P17 Q30 @default.
- Q66061370 P2899 "+18" @default.
- Q66061370 P3098 "NCT04021043" @default.
- Q66061370 P31 Q30612 @default.
- Q66061370 P4844 Q50429626 @default.
- Q66061370 P580 "2019-08-31T00:00:00Z" @default.
- Q66061370 P582 "2023-08-29T00:00:00Z" @default.
- Q66061370 P6099 Q42824440 @default.
- Q66061370 P6099 Q5452194 @default.
- Q66061370 P8363 Q78089383 @default.